Eton Pharmaceutical Stock Discussion

$Eton Pharmaceutical(ETON.US)$ Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
-- Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13(th) straight quarter of sequential product sales growth
-- Acquired PKU GOLIKE(R), launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400

$Eton Pharmaceutical(ETON.US)$ Eton Pharmaceuticals Inc - Expects Et-400 and Alkindi Sprinkle(®) to Achieve Potential Combined Peak Sales of More Than $50 Mln Annually

$Eton Pharmaceutical(ETON.US)$
Look at this buy and sell chart.. its empty

$Eton Pharmaceutical(ETON.US)$ Eton Pharmaceuticals Acquires Exclusive U.S. Rights To PKU GOLIKE From Relief Therapeutics, Expects To Be Accretive To Earnings In 2024
Moomoo 24/7· 02:29
Eton Pharmaceutical PKU GOLIKE is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call point
Transaction is expected to be accretive to 2024 earnings
Estimated peak sales of more than $10 million annually
U.S. phenylketonur...

$Eton Pharmaceutical(ETON.US)$ Thu, 14 March 2024 at 5:35 PM GMT-4
• Revenue Growth: Q4 product sales and royalty revenue surged by 109% year-over-year to $7.3 million.
• Positive Cash Flow: ETON generated $0.4 million in operating cash flow in Q4, with a cash reserve of $21.4 million.
• Research and Development: R&D expenses slightly increased to $1.0 million in Q4, supporting progress in the company's drug pipeline.
• Net Loss: ETON reported a net loss of $2.3 million in Q4...

$Eton Pharmaceutical(ETON.US)$ Eton Pharmaceuticals' ET-400 Protect Candidate Approved for US Patent
MT Newswires· 2 mins ago
Eton Pharmaceuticals (ETON) on Wednesday said it received a US patent protecting the intellectual property supporting the drug maker's ET-400 product candidate through 2043.
If successful, ET-400 will be included in FDA catalog of Approved Drug Products with Therapeutic Equivalence Evaluations, more commonly known as the Orange Book.
The comp...

$Eton Pharmaceutical(ETON.US)$ Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
1 MINUTE AGO, 6:50 AM EST
VIA GLOBENEWSWIRE

$Eton Pharmaceutical(ETON.US)$ Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
2 MINUTES AGO, 6:50 AM EST
VIA GLOBENEWSWIRE

$Eton Pharmaceutical(ETON.US)$ DEER PARK, Ill., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced it has entered into an agreement to acquire an abbreviated new drug application for Nitisinone Capsules via Oakrum Pharma, LLC's Chapter 11 bankruptcy proceeding. The tra...